Abstract
Surgery is an almost inevitable event in Crohn's disease but is not curative; post-operative recurrence follows a sequential and predictable course. Prevention of post-operative recurrence in Crohn's disease is therefore a relevant problem in the management of the disease. Several drugs have been evaluated to decrease the risk of recurrence: these include mesalazine, antibiotics, probiotics, budesonide, thiopurines and biologic agents. This review focuses on the randomised controlled trials and meta-analyses addressing different drugs and strategies for preventing post-operative recurrence in Crohn's disease.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Inflammatory Agents / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antirheumatic Agents / therapeutic use
-
Budesonide / therapeutic use
-
Combined Modality Therapy
-
Crohn Disease / drug therapy
-
Crohn Disease / prevention & control*
-
Crohn Disease / surgery
-
Drug Therapy, Combination
-
Endoscopy, Digestive System
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Infliximab
-
Interleukin-10 / therapeutic use
-
Lactobacillus
-
Mesalamine / therapeutic use
-
Meta-Analysis as Topic*
-
Multicenter Studies as Topic
-
Probiotics / therapeutic use
-
Randomized Controlled Trials as Topic / statistics & numerical data*
-
Secondary Prevention
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Immunosuppressive Agents
-
Interleukin-10
-
Mesalamine
-
Budesonide
-
Infliximab